Skip to Content
Merck

K2638

Kallikrein from human plasma

buffered aqueous solution, ≥5 units/mg protein

Synonym(s):

Kininogenase, Kininogenin

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

CAS Number:
UNSPSC Code:
12352204
NACRES:
NA.54
EC Number:
MDL number:
Specific activity:
≥5 units/mg protein
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Kallikrein from human plasma, buffered aqueous solution, ≥5 units/mg protein

form

buffered aqueous solution

specific activity

≥5 units/mg protein

UniProt accession no.

shipped in

dry ice

storage temp.

−20°C

Quality Level

Gene Information

human ... KLK1(3816)

Looking for similar products? Visit Product Comparison Guide

Application

Kallikrein from human plasma has been used:

  • to culture human hepatocellular carcinoma cell line
  • to study its effects on the cleavage of Neisserial heparin binding antigen (NHBA) from Neisseria meningitidis
  • in peptidase inhibition assay

Biochem/physiol Actions

Plasma kallikrein (PK) is involved in the synthesis of bradykinin, maintaining the blood metabolite levels and hypertension. It also participates in the activation of coagulation factor XII, which promotes inflammation and the intrinsic coagulation pathway. PK controls proteolytic cascades in the cardiovascular system like the kallikrein-kinin system, renin-angiotensin system, fibrinolytic system, and the alternative complement pathway. It is involved in the cleavage of glucagon-like peptide-1 (GLP-1) and neuropeptide Y (NPY) which suggests that plasma kallikrein may affect metabolism and diabetes.

General description

Kallikrein-related peptidases belong to the family of 15 highly conserved trypsin- or chymotrypsin-like serine proteases. Plasma kallikrein (PK) is a serine protease derived from plasma prekallikrein, a zymogen found at higher levels in blood circulation. The KLKB1 gene is located on the human chromosome at 4q35.2.

Other Notes

One unit will hydrolyze 1.0 μmole of Nα-benzoyl-L-arginine ethyl ester (BAEE) to Nα-benzoyl-L-arginine and ethanol per min at pH 8.7 at 25°C.

Physical form

Solution in 20 mM Tris-HCl, pH 7.8 with 100 mM NaCl.

Storage Class

12 - Non Combustible Liquids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, multi-purpose combination respirator cartridge (US)


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Elisa Pantano et al.
PloS one, 14(8), e0203234-e0203234 (2019-08-02)
Neisserial Heparin Binding Antigen (NHBA) is a surface-exposed lipoprotein of Neisseria meningitidis and a component of the Bexsero vaccine. NHBA is characterized by the presence of a highly conserved Arg-rich region involved in binding to heparin and heparan sulphate proteoglycans
Xueqing Xu et al.
Nucleic acids research, 37(22), 7381-7393 (2009-10-13)
A subtelomeric region, 4q35.2, is implicated in facioscapulohumeral muscular dystrophy (FSHD), a dominant disease thought to involve local pathogenic changes in chromatin. FSHD patients have too few copies of a tandem 3.3-kb repeat (D4Z4) at 4q35.2. No phenotype is associated
D Kolte et al.
British journal of pharmacology, 162(7), 1639-1649 (2010-12-24)
Kallikrein acts on high molecular weight kininogen (HK) to generate HKa (cleaved HK) and bradykinin (BK). BK exerts its effects by binding to B(2) receptors. The activation of B(2) receptors leads to the formation of tissue plasminogen activator, nitric oxide
R Dellalibera-Joviliano et al.
Scandinavian journal of immunology, 71(4), 292-297 (2010-04-14)
In the present study, we evaluated the kinin system components in the plasma of patients with systemic lupus erythematosus exhibiting mucocutaneous lesions. Fifteen women with active cutaneous lupus (P) and 15 normal healthy women (C) were studied. Low molecular (LKg)
Edward P Feener
Current diabetes reports, 10(4), 270-275 (2010-06-11)
Recent proteomic studies have identified components of the kallikrein kinin system, including plasma kallikrein, factor XII, and kininogen, in vitreous obtained from individuals with advanced diabetic retinopathy. In rodent models, activation of plasma kallikrein in vitreous increases retinal vascular permeability;

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service